Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Looming patent cliffs By 2030, more than 190 drugs will lose patent exclusivity , including 69 blockbuster drugs, putting at risk $236 billion in sales.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

M&A Leadership Council

AUGUST 15, 2022

A sell-off, which is by far the most common type of divestiture (and the type usually referred to as such), is the sale of one or more company units to another company – for example, when BF Goodrich Corporation sold its JcAIR Test Systems business to Aeroflex Incorporated in 2005. What is a sell-off? . What is a spin-off?

Mergers and Acquisitions 52

Mergers and Acquisitions IPO M&A Initial Public Offering 52

Cooley M&A

JANUARY 30, 2024

a sale, divestiture, change in strategy or management, return of capital to shareholders, etc.). Commercial-stage pharmaceutical companies with lagging share price, financial performance This group includes companies that are performing poorly relative to their peers and have perceived strategic, operational, or governance issues.

Private Equity 52

Private Equity M&A Investors Capital 52